Company intelligence / Profile preview
Immunotech Biopharm
Beijing, Chinaen.eaal.net ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Immunotech Biopharm/Beijing Yongtai Ruike Biotechnology focuses on cellular immunotherapy products including both non-genetically-modified and genetically-modified therapies such as CAR-T and TCR-T cells. Their lead program EAL® targets postsurgical recurrence of liver cancer with a completed Phase II trial enrolling over 400 patients; NDA submission to Chinese regulators expected soon. Their pipeline also includes CAR-T therapies targeting CD19 for hematologic malignancies like B-cell ALL and diffuse large B-cell lymphoma, with clinical trials ongoing through at least Phase II.
- Therapeutic areas
- HematologyImmunologyOncology
- Modalities
- CAR-T cell therapyTCR-T cell therapyCell therapy (general, including non-genetically modified and genetically modified products)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Immunotech Biopharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunotech Biopharm.